Abstract
The treatment of psychotic disorders has been dramatically changed by the discovery, in 1952, of antipsychotic activity of chlorpromazine and the definition of criteria for a new therapeutic class. Since then, although major improvements were done in terms of neurological tolerance and easiness to handle, today's antipsychotics are highly similar to former ones. Those treatments do not answer to all expectations of patients or practitioners, in particular regarding their metabolic or cardiologic side effects and potency to reduce cognitive deficit. Moreover, despite increasing understanding of the pathophysiology of schizophrenic disorders, this new knowledge is not or very little used in the field of therapeutics, justifying to resume research efforts to improve therapeutics in psychotic disorders. The development of a new medication follows several steps, based on precise strategies and regulations. The main streams of research concern compounds that act on dopaminergic, serotoninergic or peptidergic systems.
References
Feb 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P SeemanH H Van Tol
Nov 10, 2000·Pharmacopsychiatry·J Horácek
Sep 5, 2001·The American Journal of Psychiatry·D C Goff, J T Coyle
Feb 18, 2004·Current Medicinal Chemistry·M L CarlssonM Nilsson
May 1, 2004·Psychopharmacology·Patricia S Goldman-RakicGraham V Williams
Jun 19, 2004·Psychopharmacology·Joseph I Friedman
Jul 28, 2004·Molecular Psychiatry·D C Javitt
Aug 25, 2004·Neurotoxicity Research·Thérèse M JayMichael Spedding
May 11, 2005·Current Medical Research and Opinion·Roger Bullock
Jun 14, 2005·Trends in Biochemical Sciences·Volker EulenburgJesús Gomeza
Sep 10, 2005·Schizophrenia Bulletin·Alan Breier
Sep 24, 2005·Schizophrenia Bulletin·Jim J Hagan, Declan N C Jones
Dec 13, 2005·Nature Reviews. Drug Discovery·Will SpoorenHerbert Meltzer
Mar 21, 2006·Biological Psychology·Y Chudasama, T W Robbins
Apr 15, 2006·CNS & Neurological Disorders Drug Targets·P SokoloffC Gross
Apr 25, 2006·Biological Psychiatry·Jingshan ChenDaniel R Weinberger
May 16, 2006·Amino Acids·M PietraszekW Danysz
Jun 15, 2006·Cellular and Molecular Neurobiology·Joseph T Coyle
Jun 20, 2006·Neuroscience and Biobehavioral Reviews·Colm M P O'TuathaighJohn L Waddington
Jun 27, 2006·Biological Psychiatry·Craig M Powell, Tsuyoshi Miyakawa
Sep 16, 2006·Neuroscience·G Le PenM-O Krebs
Oct 5, 2006·Current Drug Targets·David L Garver
Dec 28, 2006·CNS Drugs·Mona BoulesElliott Richelson
Feb 15, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Martina BallmaierPierFranco Spano
May 16, 2007·Expert Opinion on Investigational Drugs·Martyn Wood, Charlie Reavill
Jun 27, 2007·Journal of Psychopharmacology·Charles H Large
Aug 2, 2007·Molecular Psychiatry·J A Gray, B L Roth
Aug 19, 2007·CNS & Neurological Disorders Drug Targets·J M Stone, L S Pilowsky